Baidu
map

武田收购腹腔疾病疗法TAK-101:一种含有麦醇溶蛋白的免疫修饰纳米颗粒

2019-10-22 不详 MedSci原创

武田公司收购了一项在研的腹腔疾病疗法CNP-101 / TAK-101,这家日本制药巨头现在拥有开发和商业化该药物的全球独家许可,该药物是一种含有麦醇溶蛋白的免疫修饰纳米颗粒。

武田公司收购了一项在研的腹腔疾病疗法CNP-101 / TAK-101,这家日本制药巨头现在拥有开发和商业化该药物的全球独家许可,该药物是一种含有麦醇溶蛋白的免疫修饰纳米颗粒。

该药物购自COUR,基于该公司的抗原特异性免疫耐受平台开发。武田说,这个决定是基于一项IIa期试验的结果,在该试验中,在第六天就达到了干扰素-γ(IFN-γ)点形成单位(SFU)与基线相比的主要终点。

该研究还提出了防止小肠粘膜损伤的趋势,TAK-101的恶化为0.18,而安慰剂的为0.63。

COUR公司首席执行官约翰·普伊西斯(John J. Puisis)表示:"对我们专有的重编程免疫系统纳米颗粒平台的首次人类概念验证研究得到的数据感到鼓舞"。

他继续说:"由于武田承担了腹腔疾病计划的责任,COUR将专注于推进我们针对多种其他免疫疾病(从多发性硬化症到花生过敏)的疗法。"

腹腔疾病是一种严重的自身免疫性疾病,其中摄入麸质会导致小肠发炎和受损。它可以引起包括腹痛,腹泻,恶心和呕吐的症状,长期的乳糜泻并发症可能包括营养不良,骨质疏松加速,神经系统问题以及与生殖有关的问题。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822461, encodeId=14181822461c7, content=<a href='/topic/show?id=0f5e10300e3a' target=_blank style='color:#2F92EE;'>#麦醇溶蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103007, encryptionId=0f5e10300e3a, topicName=麦醇溶蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sat Nov 30 04:34:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085573, encodeId=bce120855e33f, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Mar 31 05:34:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323407, encodeId=a83e132340e77, content=<a href='/topic/show?id=d8d5e7476de' target=_blank style='color:#2F92EE;'>#纳米颗粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77476, encryptionId=d8d5e7476de, topicName=纳米颗粒)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569378, encodeId=f50e15693e839, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374312, encodeId=75173e4312b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Oct 24 00:02:34 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822461, encodeId=14181822461c7, content=<a href='/topic/show?id=0f5e10300e3a' target=_blank style='color:#2F92EE;'>#麦醇溶蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103007, encryptionId=0f5e10300e3a, topicName=麦醇溶蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sat Nov 30 04:34:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085573, encodeId=bce120855e33f, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Mar 31 05:34:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323407, encodeId=a83e132340e77, content=<a href='/topic/show?id=d8d5e7476de' target=_blank style='color:#2F92EE;'>#纳米颗粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77476, encryptionId=d8d5e7476de, topicName=纳米颗粒)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569378, encodeId=f50e15693e839, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374312, encodeId=75173e4312b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Oct 24 00:02:34 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822461, encodeId=14181822461c7, content=<a href='/topic/show?id=0f5e10300e3a' target=_blank style='color:#2F92EE;'>#麦醇溶蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103007, encryptionId=0f5e10300e3a, topicName=麦醇溶蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sat Nov 30 04:34:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085573, encodeId=bce120855e33f, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Mar 31 05:34:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323407, encodeId=a83e132340e77, content=<a href='/topic/show?id=d8d5e7476de' target=_blank style='color:#2F92EE;'>#纳米颗粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77476, encryptionId=d8d5e7476de, topicName=纳米颗粒)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569378, encodeId=f50e15693e839, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374312, encodeId=75173e4312b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Oct 24 00:02:34 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822461, encodeId=14181822461c7, content=<a href='/topic/show?id=0f5e10300e3a' target=_blank style='color:#2F92EE;'>#麦醇溶蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103007, encryptionId=0f5e10300e3a, topicName=麦醇溶蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sat Nov 30 04:34:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085573, encodeId=bce120855e33f, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Mar 31 05:34:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323407, encodeId=a83e132340e77, content=<a href='/topic/show?id=d8d5e7476de' target=_blank style='color:#2F92EE;'>#纳米颗粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77476, encryptionId=d8d5e7476de, topicName=纳米颗粒)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569378, encodeId=f50e15693e839, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374312, encodeId=75173e4312b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Oct 24 00:02:34 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822461, encodeId=14181822461c7, content=<a href='/topic/show?id=0f5e10300e3a' target=_blank style='color:#2F92EE;'>#麦醇溶蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103007, encryptionId=0f5e10300e3a, topicName=麦醇溶蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sat Nov 30 04:34:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085573, encodeId=bce120855e33f, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Mar 31 05:34:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323407, encodeId=a83e132340e77, content=<a href='/topic/show?id=d8d5e7476de' target=_blank style='color:#2F92EE;'>#纳米颗粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77476, encryptionId=d8d5e7476de, topicName=纳米颗粒)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569378, encodeId=f50e15693e839, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374312, encodeId=75173e4312b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Oct 24 00:02:34 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
    2019-10-24 zhangyxzsh
  6. [GetPortalCommentsPageByObjectIdResponse(id=1822461, encodeId=14181822461c7, content=<a href='/topic/show?id=0f5e10300e3a' target=_blank style='color:#2F92EE;'>#麦醇溶蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103007, encryptionId=0f5e10300e3a, topicName=麦醇溶蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Sat Nov 30 04:34:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085573, encodeId=bce120855e33f, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Mar 31 05:34:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323407, encodeId=a83e132340e77, content=<a href='/topic/show?id=d8d5e7476de' target=_blank style='color:#2F92EE;'>#纳米颗粒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77476, encryptionId=d8d5e7476de, topicName=纳米颗粒)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569378, encodeId=f50e15693e839, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Thu Oct 24 11:34:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374312, encodeId=75173e4312b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Oct 24 00:02:34 CST 2019, time=2019-10-24, status=1, ipAttribution=)]
    2019-10-24 thm112988

    0

相关资讯

武田、创行“智慧医养 美好生活”医养服务创新项目圆满结束

由武田、创行和上海市慈善基金会开展“智慧医养,美好生活”医养服务创新项目圆满结束。该为期一年的大学生社会创新挑战赛旨在响应国家“十三五”规划的号召,鼓励医学类专业大学生与其他学科学生跨界合作创新,运用各自专业知识,开展社会实践,针对老年人群体创新养老服务、慢性病健康护理这两大主题献计献力, 一起应用创新解决方案创造可持续、更美好的生活品质,以此来提升老龄人口的生活质量,社交生活乐趣,也为病患老龄人

NEJM:完胜Humira!武田Entyvio治疗UC的III期临床进一步结果出炉

9月26日,武田制药宣布评估肠道选择性新型抗炎药Entyvio(vedolizumab)治疗溃疡性结肠炎(UC)的III期临床VARSITY(NCT02497469)的进一步结果已发表于《新英格兰医学杂志》。

武田、微软和欧洲罕见病组织发布报告 为罕见病患者提供行动建议

昨日,时值国际罕见病日之际,由武田、微软和欧洲罕见病组织(EURODIS,由800多个罕见疾组织联合组建)共同创立的消除罕见病患儿诊断壁垒全球委员会(简称“全球委员会”)正式发布《消除罕见病患儿诊断壁垒调查结果和建议报告》(简称“报告”),总结罕见病患者在诊断方面存在的主要障碍,并提出克服这些障碍的可行建议。自2月20日起,该报告在全球重磅发布,并在美国纽约、比利时布鲁塞尔的微软办公室以及北京

武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终

Takeda宣布其针对复发或难治性系统性轻链(AL)淀粉样变性患者的3期临床研究TOURMALINE-AL1试验由于未达到其主要终点,提前结束。

武田与新生物技术公司Ambys合作开发肝病药物

武田已经与新成立的生物技术Ambys药物公司达成了1亿美元的合作关系,以支持其对严重肝病患者的治疗方法的发现和开发。Ambys正在寻求多种策略来开发针对慢性肝病患者的新药物,包括肝细胞移植的细胞治疗、肝再生的基因治疗以及替代蛋白质功能丧失的药物治疗。与此同时,Ambys获得了Third Rock Ventures和武田投资公司(Takeda)资助的6000万美元A轮融资。"我们很高兴武田一开始就加

武田宣布恩莱瑞®在中国获批 多发性骨髓瘤开启全口服治疗时代

2018年4月17日,中国上海 – 今日,武田中国正式宣布恩莱瑞®(伊沙佐米)已获得国家食品药品监督管理总局(CFDA)的批准,将联合来那度胺和地塞米松作为首个全口服治疗方案,用于治疗已接受过至少一种既往治疗的多发性骨髓瘤成人患者。

Baidu
map
Baidu
map
Baidu
map